drugset / Trial / NCT04569409

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.

NCT04569409

Phase 3 Completed 104 enrolled Anterogen Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Wagner grade 2 Foot Ulcer, compared to placebo therapy.

Timeline

Start
2020-07-14
Primary completion
2024-12-05
Completion
2024-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy

Indications